title: Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.
abstract: OBJECTIVE
  The objective of this randomised phase II study was to evaluate the impact in terms of response and toxicities of induction or consolidation chemotherapy respectively before or after concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer.
  
  
  METHODS
  In the induction arm, patients received induction chemotherapy with cisplatin (80 mg/m(2)) and paclitaxel (200 mg/m(2)) on days 1 and 29 followed by a concurrent chemoradiotherapy (66 Gy in 33 fractions, cisplatin 80 mg/m(2) days 1, 29 and 57, vinorelbine 15 mg/m(2) days 1, 8, 29, 36, 57 and 64). In consolidation arm, the same concurrent chemoradiotherapy began on day 1 followed by two cycles of cisplatin and paclitaxel.
  
  
  RESULTS
  One hundred twenty seven patients were randomised. The intent to treat response rates in induction and consolidation arms were 58% and 56% respectively. Median survival was 19.6 months in induction arm and 16.3 months in consolidation arm and 4-year survival rates were 21% and 30% respectively. Haematologic and non-haematologic toxicities were similar in both arms, except grade 3/4 oesophagitis, more frequent in consolidation arm than in induction arm (17% versus 10%).
  
  
  CONCLUSIONS
  Cisplatin-based chemotherapy as induction or consolidation with concurrent chemoradiotherapy can be administrated safely. Response rates were similar in both arms with a trend in favour for consolidation arm for long-term survival.
authors.affiliation: University Hospital Saint-Etienne, France. Electronic address: pierre.fournel@icloire.fr.
authors.forename: Pierre
authors.initials: P
authors.lastname: Fournel
authors.affiliation: University Hospital Limoges, France.
authors.forename: Alain
authors.initials: A
authors.lastname: Vergnenégre
authors.affiliation: University Hospital Brest, France.
authors.forename: Gilles
authors.initials: G
authors.lastname: Robinet
authors.affiliation: University Hospital Rennes, France.
authors.forename: Hervé
authors.initials: H
authors.lastname: Léna
authors.affiliation: Centre F. Baclesse, Caen, France.
authors.forename: Radj
authors.initials: R
authors.lastname: Gervais
authors.affiliation: General Hospital Draguignan, France.
authors.forename: Hervé
authors.initials: H
authors.lastname: Le Caer
authors.affiliation: University Hospital Lyon, France.
authors.forename: Pierre-Jean
authors.initials: PJ
authors.lastname: Souquet
authors.affiliation: General Hospital Antibes, France.
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Chavaillon
authors.affiliation: Clinical Research University Institute, Montpellier, France.
authors.forename: Marie-Cécile
authors.initials: MC
authors.lastname: Bozonnat
authors.affiliation: Clinical Research University Institute, Montpellier, France.
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Daurès
authors.affiliation: CHI Creteil, Créteil, France.
authors.forename: Christos
authors.initials: C
authors.lastname: Chouaid
authors.affiliation: Centre Léon Bérard, Lyon, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Martel-Lafay
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D002945:Cisplatin / Q000627:therapeutic use; D060830:Consolidation Chemotherapy / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D060828:Induction Chemotherapy / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome; D014747:Vinblastine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077235:Vinorelbine
chemical_list: D014747:Vinblastine; D017239:Paclitaxel; D002945:Cisplatin; D000077235:Vinorelbine
keywords: Chemotherapy; Lung cancer; Radiotherapy; Therapeutics